Overview

AlloNK, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Status:
RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjgren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
Phase:
PHASE2
Details
Lead Sponsor:
Artiva Biotherapeutics, Inc.